9 8 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • J u l y 2 0 1 8
• Cypass Micro-Stent. The Cypass Micro-Stent, which bypasses
Schlemm's canal to channel aqueous to the supraciliary space, should
be easier to use now that it comes in a preloaded version. Originally
staff needed to assemble the Cypass insertion apparatus by inserting
an applier into a loading device, extending the guidewire through the
lumen of the Cypass and then pulling the applier out. Now the stent
comes preloaded. Just pick up the applier, fully depress the reset but-
ton and the Micro-Stent is loaded onto the applier.
"MIGS is a very exciting part of glaucoma treatment. It's changing
the way we think about glaucoma and glaucoma surgery," says Dr.
Lahners. "The ability to take an extra 30 to 60 seconds more at the
end of cataract surgery and help reduce IOP is exciting. This is a lit-
tle more powerful than the devices that bypass the trabecular mesh-
work. Of course they also carry the risk of hypotony."
In the 2-year Compass trial, the Cypass achieved a mean IOP drop
of 7.4 mm Hg. And 85% of subjects were able to cease using glaucoma
medications altogether.
The ASC facility fee for the Cypass procedure (code 0474T) is
$2,440. For hospitals, it's $3,610.75.
• Dr. Lahners (left) inspects the Cypass Micro-Stent.
